{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:13:52Z","timestamp":1780470832453,"version":"3.54.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000023","name":"Government of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000023","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000092","name":"Ontario Genomics Institute","doi-asserted-by":"publisher","award":["OGI-148"],"award-info":[{"award-number":["OGI-148"]}],"id":[{"id":"10.13039\/501100000092","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008762","name":"Genome Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013873","name":"Government of Ontario","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013873","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jcf.2023.04.013","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T15:46:45Z","timestamp":1682351205000},"page":"933-940","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cost-effectiveness analysis of genetic tools to predict treatment response in patients with cystic fibrosis"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7216-064X","authenticated-orcid":false,"given":"Yeva","family":"Sahakyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2788-4179","authenticated-orcid":false,"given":"Lusine","family":"Abrahamyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4057-6592","authenticated-orcid":false,"given":"Felix","family":"Ratjen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Bear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Strug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.W.","family":"Eckford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1320-477X","authenticated-orcid":false,"given":"John K.","family":"Peel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray","family":"Krahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2128-9133","authenticated-orcid":false,"given":"Beate","family":"Sander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2023.04.013_bib0001","series-title":"The Canadian cystic fibrosis registry 2020 annual data report","year":"2020"},{"issue":"1","key":"10.1016\/j.jcf.2023.04.013_bib0002","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s41669-019-0144-1","article-title":"Health state utility data in cystic fibrosis: a systematic review","volume":"4","author":"Mohindru","year":"2020","journal-title":"Pharmacoecon Open"},{"issue":"5","key":"10.1016\/j.jcf.2023.04.013_bib0003","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1164\/rccm.200505-840OE","article-title":"Cystic fibrosis since 1938","volume":"173","author":"Davis","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"18","key":"10.1016\/j.jcf.2023.04.013_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta18180","article-title":"Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis","volume":"18","author":"Whiting","year":"2014","journal-title":"Health Technol Assess"},{"issue":"2","key":"10.1016\/j.jcf.2023.04.013_bib0005","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s12325-018-0860-4","article-title":"Efficacy and Safety of CFTR Corrector and Potentiator Combination Therapy in Patients with Cystic Fibrosis for the F508del-CFTR Homozygous Mutation: a Systematic Review and Meta-analysis","volume":"36","author":"Wu","year":"2019","journal-title":"Adv Ther"},{"issue":"19","key":"10.1016\/j.jcf.2023.04.013_bib0006","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for cystic fibrosis with a single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.jcf.2023.04.013_bib0007","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2023.04.013_bib0008","unstructured":"Canadian Agency for Drug and Technologies in Health. CADTH Reimbursement Recommendation. Elexacaftor-Tezacaftor-Ivacaftor and Ivacaftor (Trikafta). Ottawa, Canada: CADTH; 2022. Available from: https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/SR0710%20Trikafta%20-%20Draft%20CADTH%20Recommendation%2C%20May%2019%2C%202022_for%20posting.pdf."},{"issue":"1","key":"10.1016\/j.jcf.2023.04.013_bib0009","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jcf.2018.03.013","article-title":"The CF Canada-Sick Kids Program in individual CF therapy: a resource for the advancement of personalized medicine in CF","volume":"18","author":"Eckford","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2023.04.013_bib0010","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.jcf.2023.04.013_bib0011","first-page":"4590","article-title":"Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics","volume":"25","author":"Strug","year":"2016","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jcf.2023.04.013_bib0012","series-title":"Canadian agency for drug and technologies in health. Guidelines for the economic evaluation of health technologies","year":"2017"},{"key":"10.1016\/j.jcf.2023.04.013_bib0013","unstructured":"TreeAge Pro 2021, R1.0. TreeAge Software, Williamstown, MA; Software, https:\/\/www.treeage.com."},{"issue":"3","key":"10.1016\/j.jcf.2023.04.013_bib0014","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jcf.2019.03.002","article-title":"Lung transplant referral for individuals with cystic fibrosis: cystic Fibrosis Foundation consensus guidelines","volume":"18","author":"Ramos","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2023.04.013_bib0015","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(16)30427-1","article-title":"Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study","volume":"5","author":"Konstan","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.jcf.2023.04.013_bib0016","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1136\/thorax.56.3.218","article-title":"Assessment of quality of life in lung transplantation using a simple generic tool","volume":"56","author":"Anyanwu","year":"2001","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.jcf.2023.04.013_bib0017","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S1569-1993(02)00079-6","article-title":"Validation of the SF-36 for the assessment of quality of life in adolescents and adults with cystic fibrosis","volume":"1","author":"Gee","year":"2002","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2023.04.013_bib0018","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40273-013-0122-x","article-title":"The cost effectiveness of dry powder antibiotics for the treatment of Pseudomonas aeruginosa in patients with cystic fibrosis","volume":"32","author":"Tappenden","year":"2014","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jcf.2023.04.013_bib0019","article-title":"Modulator treatments for cystic fibrosis: effectiveness and value; evidence report and meeting summary","author":"Tice","year":"2020","journal-title":"Inst Clin Econ Rev"},{"key":"10.1016\/j.jcf.2023.04.013_bib0020","unstructured":"Government of Ontario. Ministry of Health and Long-Term Care. OHIP Schedule of benefits and fees, https:\/\/www.health.gov.on.ca\/en\/pro\/programs\/ohip\/sob\/; 2020 [accessed 12 December 2020]."},{"key":"10.1016\/j.jcf.2023.04.013_bib0021","first-page":"1","article-title":"Hospital costs of Canadian cystic fibrosis patients","author":"Skolnik","year":"2021","journal-title":"Can J Respiratory, Crit Care, Sleep Med"},{"issue":"3","key":"10.1016\/j.jcf.2023.04.013_bib0022","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.healun.2022.10.016","article-title":"Determining the impact of ex-vivo lung perfusion on hospital costs for lung transplantation: a retrospective cohort study","volume":"42","author":"Peel","year":"2023","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jcf.2023.04.013_bib0023","unstructured":"Statistics Canada. Consumer price index, annual average, not seasonally adjusted. Table 18-10-0005-01 [accessed 28 March 2023]."},{"issue":"3","key":"10.1016\/j.jcf.2023.04.013_bib0024","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jcf.2013.10.012","article-title":"Cost effectiveness of newborn screening for cystic fibrosis: a simulation study","volume":"13","author":"Nshimyumukiza","year":"2014","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.04.013_bib0025","unstructured":"Government of Ontario. Ontario Drug Benefit Formulary\/Comparative Drug Index, https:\/\/www.formulary.health.gov.on.ca\/formulary\/; 2020 [accessed 12 December 2020]."},{"issue":"6","key":"10.1016\/j.jcf.2023.04.013_bib0026","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1183\/13993003.01444-2015","article-title":"Forecasting US ivacaftor outcomes and cost in cystic fibrosis patients with the G551D mutation","volume":"47","author":"Dilokthornsakul","year":"2016","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.jcf.2023.04.013_bib0027","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jcf.2020.07.017","article-title":"Projecting the impact of delayed access to elexacaftor\/tezacaftor\/ivacaftor for people with Cystic Fibrosis","volume":"20","author":"Stanojevic","year":"2021","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323001194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323001194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T22:07:15Z","timestamp":1762553235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199323001194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1569199323001194"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2023.04.013","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness analysis of genetic tools to predict treatment response in patients with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2023.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}